Lac

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythe results from two Phase II non-randomized studies of seliciclibfixed dose combinations. In one study seliciclib was given incombination with gemcitabine and cisplatin and in another withdocetaxel in patients with advanced non-small cell lung cancer(NSCLC).<p...

Next Safety, Inc.'s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,Inc. has identified basic scientific mechanisms that promise torevolutionize pulmonary drug delivery. This proprietary technologyuses a stream of purified air to deliver medications deep into thepulmonary system. It is considered superior to other drug deliverysystems because it rapidly administers aerosolized drugs to thelin...

Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo

Demonstrates Positive Effect on Objective and Subjective SleepMeasures MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- Accordingto study results presented today at SLEEP 2007, the 21st annualmeeting of the Associated Professional Sleep Societies (APSS),VEC-162, a balanced melatonin (MT1/MT2) receptor agonist beingdeveloped by Vanda Pharmaceuticals Inc. , demonstrated improvementsin...

Women Well-Informed About Breast Cancer, Yet Lacking Knowledge About Current Treatments, New Survey Finds

-- CancerCare offers five questions to help womenlearn about breast cancer therapy advances -- NEW YORK, June 12, 2007 – According to a newGfK Roper Public Affairs survey sponsored by CancerCare, a nationalnonprofit cancer support organization, while the majority (76percent) of women surveyed said they know at least a fair amountabout breast cancer...

Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA

OSLO, Norway, 11 June 2007 - Clavis Pharma (OSE: CLAVIS)presented an update of data from its ongoing clinical Phase I/IIstudy with ELACYT in hematologic cancers during a poster session atthe Annual Meeting of the European Hematology Association (EHA) inVienna. ELACYT is a novel cytotoxic agent in development for thetreatment of hematologic cancers as well as for solid tumours. Inthis ong...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCOProceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancerresearcher affiliated with the US Oncology Research Networkpresented findings from a randomized, multicenter phase III trialthat compared the disease-free survival (DFS) obtained with tworegimens of adjuvant therapy for patients with high-risk breastcancer. Th...

Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo

NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. and PAION AG today announced topline results ofthe DIAS-2 (Desmoteplase In Acute Ischemic Stroke) study with thecompound Desmoteplase. The Phase III study was designed toinvestigate the improvement of clinical outcome in patients withacute ischemic stroke treated with Desmoteplase within 3 to 9 hoursafter onset of...

Top Line Results of Phase III Study in Acute Ischemic Stroke (DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo

PAION AG and US Partner Forest Laboratories, Inc. TodayAnnounced the Top Line Results of the DIAS-2 (Desmoteplase In AcuteIschemic Stroke) Study with the Compound Desmoteplase Aachen (Germany), May 31st, 2007 - PAION AG (Frankfurt StockExchange, Prime Standard: PA8) and its US partner ForestLaboratories, Inc. (NYSE: FRX) today announced topline results ofthe DIAS-2 (Desmoteplase In...

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--May 24, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythat it will report results from a Phase I pharmacologic trial ofsapacitabine (CYC682), a novel orally-available nucleoside analog,in patients with advanced leukemias or myelodysplastic syndromes(MDS), at the American Society of Clinical Oncology's (ASCO) Annual...

New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia

Six-Month Data Show Bifeprunox Maintained StabilitySignificantly Longer than Placebo and had a Favorable Weight andLipid Profile Comparable with Placebo MARIETTA, Ga. and COLLEGEVILLE, Pa., May 22, 2007 - SolvayPharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth(NYSE:WYE), and Lundbeck A/S presented clinical study results onbifeprunox, an investigational treatment for...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

Pooled Findings Presented at 2007 APA Meeting Also Showed NoSignificant Impact on Weight for Desvenlafaxine Succinate COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ --Findings from two separate pooled analyses - one examining theeffect of desvenlafaxine succinate on anxious symptoms and theother on painful symptoms associated with major depressive disorder(MDD) -- as well as a sep...

Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy

Cytos Biotechnology reports positive results from placebocontrolled phase IIa study in patients suffering from house dustmite allergy SCHLIEREN (Zurich), Switzerland, May 15, 2007 - Cytos BiotechnologyAG (SWX:CYTN) reported today positive results from a multi-centreand placebo-controlled phase IIa study with different formulationsof CYT003-QbG10, an immunotherapeutic product can...

New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace

First comprehensive study of market dynamics offers insights intowhat will be needed to get new, faster and better TB drugs topatients NEW YORK, May 14, 2007 /PRNewswire-USNewsire/ -- The GlobalAlliance for TB Drug Development (TB Alliance), a not-for-profit,product development partnership accelerating the discovery anddevelopment of new TB drugs, today released results from the firstcom...

Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies

-- Large multi-year, multi-hospital retrospective database analysisdemonstrates RDS treatment with Curosurf(R) (poractant alfa)Intratracheal Suspension provides significantly improved neonatalsurvival -- NAPA, Calif. and PARMA, Italy, May 07, 2007 /PRNewswire/ -- Datapresented today at the Pediatric Academic Societies' Annual Meetingdemonstrate that premature infants with neonatal Respira...

Advanced Magnetics Announces Positive Results from Two Additional Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapeutic

CAMBRIDGE, Mass., April 11, 2007 /PRNewswire-FirstCall/ --Advanced Magnetics today announced positive results from twoadditional Phase III clinical trials of ferumoxytol as anintravenous (IV) iron replacement therapeutic that are beingpresented today at approximately 6:00 pm EDT as posters at theNational Kidney Foundation's Spring Clinical Meeting in Orlando,Florida. These posters are av...

Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 11, 2007 - CyclacelPharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announcedtoday that scientists from the company will present results of twopreclinical studies with sapacitabine and seliciclib, the company'smost advanced drug candidates in clinical development. The resultswill be reported in two poster presentations during the upcomingAnnu...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

Data to be Presented at the XXI Congress of the InternationalSociety on Thrombosis and Haemostasis SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRNewswire/ --Portola Pharmaceuticals, Inc. today announced that it has receivedpositive results from EXPERT, a Phase II study of its oral FactorXa inhibitor, PRT054021, for the prevention of venousthromboembolism (VTE) following total knee replac...

Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo

COLLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstCall/ --Wyeth Pharmaceuticals, a division of Wyeth , SolvayPharmaceuticals, Inc. and Lundbeck A/S presented clinical studyresults on bifeprunox at an international medical congress thisweek. Safety analyses suggest bifeprunox, an investigationaltreatment for adult patients diagnosed with schizophrenia, wasassociated with a favorable weig...

Survey Reveals Significant Public Lack of Diabetes Awareness

MINNEAPOLIS--(BUSINESS WIRE)--Mar 27, 2007 - According to a recentnationwide survey released today, nearly 80 percent of the Americanpublic does not know the difference between type 1 and type 2diabetes. The survey, conducted by Harris Interactive(R) andcommissioned by Medtronic, Inc. (NYSE:MDT), showed that almost halfof respondents were also unaware that two distinct forms ofdiabetes exis...

Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients

SCHLIEREN (Zurich), Switzerland, March 13, 2007 -Cytos Biotechnology AG (SWX:CYTN) reported today positive resultsfrom a phase IIa study with CYT003-QbG10, an immunotherapeuticproduct candidate for the treatment of allergic diseases. The studyincluded 40 patients suffering from mild to moderate allergicrhinitis due to grass pollen allergy (hay fever). The trialinvestigated i...